GlaxoSmithKline and Genmab launch ofatumumab study

GlaxoSmithKline and Genmab are launching a phase III clinical trial assessing a new formulation of their drug ofatumumab in the treatment of a serious autoimmune condition.

The study will be the first phase III trial to involve the subcutaneous version of ofatumumab and will evaluate the compound's safety and efficacy against pemphigus vulgaris, a rare autoimmune disorder of the skin.

Patients affected by this condition experience a malfunction of the immune system that produces antibodies to attack healthy cells in the skin and mucous membranes, creating  burn-like blisters and sores and often leading to secondary conditions.

The phase III study will involve around 136 patients and will aim to achieve better disease remission rates than placebo.

Dr Jan van de Winkel, chief executive officer of Genmab, said: "We are pleased that GlaxoSmithKline are investigating ofatumumab in the treatment of pemphigus vulgaris, a seriously debilitating and sometimes life-threatening autoimmune disease."

This comes after GlaxoSmithKline recently received recommendations from Europe's Committee for Medicinal Products for Human Use for Tafinlar and Tyverb, two new therapies for advanced forms of cancer.